Biodefense and special pathogen vaccines

Vaccines

Volumn , Issue , 2008, Pages 1123-1133

  Pittman, Phillip ^a   Plotkin, Stanley A ^b  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 66749120185     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3611-1.50044-1     Document Type: Chapter

References (148)

1. PR Pittman, KM Coonar, PH Gibbs, HM Scott, KI McKee Jr and TL Cannon (2004) Long-term health effects of repeated exposure to multiple vaccines. Vaccine 23 525-536.
2. PR Pittman, SL Norris, KM Coonan and KT McKee Jr (2005) An assessment of health status among medical research volunteers who served in the Project Whitecoat program at Fort Detrick, Maryland. Mil Med 170(3), 183-187.
3. EG Westaway, MA Brinton, SY Gaidamovich, et al. (1985) Flaviviridae. Intervirology 24(4), 183-192.
4. J Casals (1957) Flavivridae. Intervirology 19 219-235.
5. AT De Madrid and JS Porterfield (1974) The flaviviruses (group B arboviruses): a cross-neutralization study. J Gen Virol 23(1), 91-96.
6. CH Calisher, N Karabatsos, JM Dalrymple, et al. (1989) Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera. J Gen Virol 70(Pt 1), 37-43.
7. DH Clarke (1964) Further studies on antigenic relationships among the viruses of the group b tick-borne complex. Bull World Health Organ 31 45-56.
8. FW Cole, SW May and GA Eddy (1974) Inactivated Venezuelan equine encephalomyelitis virus prepared from attenuated (TC-83) virus. Applied Micrbiol 27 150-153.
9. JE Salk, U Krech, JS Youngner, et al. (1954) Formaldehyde treatment and safety testing of experimental poliomyelitis vaccines. Am J Public Health 44(5), 563-570.
10. PR Pittman, RS Makuch, JA Mangiafico, et al. (1996) Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine. Vaccine 14(4), 337-343.
11. NL Davis, KW Brown, GF Greenwald, et al. (1955) Attenuated mutants of Venezuelan equine encephalitis virus containing lethal mutations in the PE2 cleavage signal combined with a second-site suppressor mutation in E1. Virology 212(1), 102-110.
12. V Rao, ME Hinz, BA Roberts and D Fine (2006) Toxicity assessment of Venezuelan equine encephalitis virus vaccine candidate strain V3526. Vaccine 24(10), 1710-1715.
13. DM Robinson, S Berman, JP Lowenthal and FM Hetrick (1966) Western equine encephalomyelitis vaccine produced in chick embryo cell cultures. Appl Microbiol 14(6), 1011-1014.
14. PJ Bartelloni, RW McKinney, FM Calia, et al. (1971) Inactivated western equine encephalomyelitis vaccine propagated in chick embryo cell culture. Clinical and serological evaluation in man. Am J Trop Med Hyg 20(1), 146-149.
15. PR Pittman (1999) Immunization of persons at risk of exposure to eastern equine encephalitis virus: continued assessment of the safety and effectiveness of eastern equine encephalitis vaccine, inactivated, TSI-GSD 104 (Protocol No IND 266:FY99–11) Ft Detrick, MD: U.S. Army Medical Research Institute of Infectious Diseases
16. LF Maire III, RW McKinney and FE Cole Jr (1970) An inactivated eastern equine encephalomyelitis vaccine propagated in chick-embryo cell culture. I. Production and testing. Am J Trop Med Hyg 19(1), 119-122.
17. JJ Deller Jr and PK Russell (1968) Chikungunya disease. Am J Trop Med Hyg 17(1), 107-111.
18. AC Kennedy, J Fleming and L Solomon (1980) Chikungunya viral arthropathy: a clinical description. J Rheumatol 7(2), 231-236.
19. RE Johnston and CJ Peters (1996) Alphaviruses. Fields’ Virology, 3rd ed Philadelphia: Lippincott-Raven 843-898.
20. C Paquet, I Quatresous, JL Solet, et al. (2006) Chikungunya outbreak in Reunion: epidemiology and surveillance, 2005 to early January 2006. Euro Surveill 11(2), E060202.
21. I Schuffenecker, I Iteman, A Michault, et al. (2006) Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak. PLoS Med 3(7), e263.
22. NH Levitt, HH Ramsburg, SE Hasty, et al. (1986) Development of an attenuated strain of Chikungunya virus for use in vaccine production. Vaccine 4(3), 157-162.
23. R Edelman, CO Tacket, SS Wasserman, et al. (2000) Phase II safety and immunogenicity study of live Chikungunya virus vaccine TSI-GSD-218. Am J Trop Med Hyg 62(6), 681-685.
24. JR Nimmo (1928) An unusual epidemic. Med J Aust 1 549-550.
25. RL Doherty, RH Whitehead, BM Gorman and AK O'Gower (1963) The isolation of a third group-A arbovirus in Australia with preliminary observations on its relationship to epidemic polyarthritis. Aust J Sci 26 183-184.
26. RL Doherty, RH Whitehead, EJ Wetters and BM Gorman (1968) Studies of the epidemiology of arthropod-borne virus infections at Mitchell River Mission, Cape York Peninsula, North Queensland. II. Arbovirus infections of mosquitoes, man and domestic fowls, 1963–1966. Trans R Soc Trop Med Hyg 62(3), 430-438.
27. ID Marshall and JAR Miles (1984) Ross River virus and epidemic polyarthritis. KF Harris (Eds) Current Topics in Vector Research New York: Praeger 31-56. 2
28. NE Rulli, A Suhrbier, L Hueston, et al. (2005) Ross River virus: molecular and cellular aspects of disease pathogenesis. Pharmacol Ther 107(3), 329-342.
29. RC Russel, SE Cope, AJ Yung, et al. (1998) Combating the enemy–mosquitoes and Ross River virus in a joint military exercies in tropical Australia. Am J Trop Med Hyg 59 S307.
30. S Yu and JG Aaskov (1994) Development of a candidate vaccine against Ross River virus infection. Vaccine 12(12), 1118-1124.
31. J Aaskov, L Williams and S Yu (1997) A candidate Ross River virus vaccine: preclinical evaluation. Vaccine 15(12–13), 1396-1404.
32. ML Linn, JG Aaskov and A Suhrbier (1996) Antibody-dependent enhancement and persistence in macrophages of an arbovirus associated with arthritis. J Gen Virol 77(Pt 3), 407-411.
33. Q Li, D Niu, B Wen, et al. (2005) Protective immunity against Q fever induced with a recombinant P1 antigen fused with HspB of Coxiella burnetii. Ann N Y Acad Sci 1063 130-142.
34. NR Parker, JH Barralet and AM Bell (2006) Q fever. Lancet 367(9511), 679-688.
35. G Pier (2005) Application of vaccine technology to prevention of Pseudomonas aeruginosa infections. Expert Rev Vaccines 4(5), 645-656.
36. E Sedlak-Weinstein, AW Cripps, JM Kyd and AR Foxwell (2005) Pseudomonas aeruginosa: the potential to immunise against infection. Expert Opin Biol Ther 5(7), 967-982.
37. H Caplen, CJ Peters and DH Bishop (1985) Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. J Gen Virol 66(Pt 10), 2271-2277.
38. JC Morrill, L Carpenter, D Taylor, et al. (1991) Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep. Vaccine 9(1), 35-41.
39. A Baskerville, KA Hubbard and JR Stephenson (1992) Comparison of the pathogenicity for pregnant sheep of Rift Valley fever virus and a live attenuated vaccine. Res Vet Sci 52(3), 307-311.
40. JC Morrill, CA Mebus and CJ Peters (1997) Safety of a mutagen-attenuated Rift Valley fever virus vaccine in fetal and neonatal bovids. Am J Vet Res 58(10), 1110-1114.
41. JC Morrill, CA Mebus and CJ Peters (1997) Safety and efficacy of a mutagen-attenuated Rift Valley fever virus vaccine in cattle. Am J Vet Res 58(10), 1104-1109.
42. PR Pittman (1999) Evaluation of the safety and immunogenicity of Rift Valley fever vaccine (live, attenuated, mutagenized (ZH548 MP-12 TSI-GSD-223-Lot 7-2-88)) administered subcutaneously or intramuscularly: final report to the Food and Drug Administration Ft Detrick, MD: U.S. Army Medical Research Institute of Infectious Diseases
43. EB Hayes, JJ Sejvar, SR Zaki, et al. (2005) Virology, pathology, and clinical manifestations of West Nile virus disease. Emerg Infect Dis 11(8), 1174-1179.
44. RB Tesh, J Arroyo, R. Travassos Da Rosa, et al. (2002) Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunizaiton for prevention of West Nile virus encephalitis in hamster model. Emerg Infect Dis 8(12), 1392-1397.
45. TP Monath, J Liu, N Kanesa-Thasan, et al. (2006) A live, attenuated recombinant West Nile virus vaccine. Proc Natl Acad Sci USA 103(17), 6694-6699.
46. L Siger, R Bowen, K Karaca, et al. (2006) Evaluation of the efficacy provided by a Recombinant Canarypox-Vectored Equine West Nile Virus vaccine against an experimental West Nile Virus intrathecal challenge in horses. Vet Ther 7(3), 249-256.
47. K Karaca, R Bowen, LE Austgen, et al. (2005) Recombinant canarypox vectored West Nile virus (WNV) vaccine protects dogs and cats against a mosquito WNV challenge. Vaccine 23 3808-3813.
48. RA Hall and A Khromykh (2004) West Nile virus vaccines. Expert Opin Biol Ther 4(8), 1295-1305.
49. A Seregin, R Nistler, V Borisevich, et al. (2006) Immunogenicity of West Nile infectious DNA and its noninfectious derivatives. Virology 356(1–2), 115-125.
50. HW Lee (1989) Hemorrhagic fever with renal syndrome in Korea. Rev Infect Dis 11(Suppl4), S864-S876.
51. C Schmaljohn and B Hjelle (1997) Hantaviruses: a global disease problem. Emerg Infect Dis 3(2), 95-104.
52. B Hjelle (2002) Vaccines against hantaviruses. Expert Rev Vaccines 1(3), 373-384.
53. HW Lee, PW Lee and KM Johnson (1978) Isolation of the etiologic agent of Korean hemorrhagic fever. J Infect Dis 137(3), 298-308.
54. ST Nichol, CF Spiropoulou, S Morzunov, et al. (1993) Genetic identification of a Hantavirus associated with an outbreak of acute respiratory illness. Science 262(5135), 914-917.
55. HWACN Lee (1990) Field trial of an inactivated vaccine against HFRS in humans. Arch virol Suppl 1 35-47.
56. A major breakthrough in preventive medicine: Hantavirus (HFRS vaccine, KGCC) Seoul, Korea: Korea Green Cross Organization
57. HW Cho and CR Howard (1999) Antibody responses in humans to an inactivated Hantavirus vaccine (Hantavax). Vaccine 17(20–21), 2569-2575.
58. JW Hooper and D Li (2001) Vaccines against Hantaviruses. Curr Top Microbiol Immunol 256 171-191.
59. DH Kruger, R Ulrich and AA Lundkvist (2001) Hantavirus infections and their prevention. Microbes Infect 3 1129-1144.
60. HW Cho, CR Howard and HW Lee (2002) Review of an inactivated vaccine against Hantaviruses. Intervirology 45(4–6), 328-333.
61. K Park, CS Kim and KT Moon (2004) Protective effectiveness of Hantavirus vaccine. Emerg Infect Dis 10(12), 2218-2220.
62. Y Choi, CJ Ahn, KM Seong, MY Jung and BY Ahn (2003) Inactivated Hantaan virus vaccine derived from suspension culture of Vero cells. Vaccine 21(17–18), 1867-1873.
63. CS Schmaljohn, SE Hasty and JM Dalrymple (1992) Preparation of candidate vaccinia-vectored vaccines for haemorrhagic fever with renal syndrome. Vaccine 10(1), 10-13.
64. DJ McClain, PL Summers, SA Harrison, et al. (2000) Clinical evaluation of a vaccinia-vectored Hantaan virus vaccine. J Med Virol 60(1), 77-85.
65. DM Custer, E Thompson, CS Schmaljohn, et al. (2003) Active and passive vaccination against Hantavirus pulmonary syndrome with Andes virus M genome segment-based DNA vaccine. J Virol 77(18), 9894-9905.
66. JW Hooper, DM Custer, J Smith and V Wahl-Jensen (2006) Hantaan/Andes virus DNA vaccine elicits a broadly cross-reactive neutralizing antibody response in nonhuman primates. Virology 347(1), 208-216.
67. R Ulrich, D Koletzki, S Lachmann, et al. (1999) New chimaeric hepatitis B virus core particles carrying Hantavirus (serotype Puumala) epitopes: immunogenicity and protection against virus challenge. J Biotechnol 73(2–3), 141-153.
68. P Maes, J Clement, I Gavrilovskaya and M Van Ranst (2004) Hantaviruses: immunology, treatment and prevention. Viral Immunol 17(4), 481-497.
69. JG Barrera Oro, KT McKee Jr, J Spisso, et al. (1990) A refined complement-enhanced neutralization test for detecting antibodies to Junin virus. J Virol Methods 29(1), 71-80.
70. JI Maiztegui (1975) Clinical and epidemiological patterns of Argentine haemorrhagic fever. Bull World Health Organ 52(4–6), 567-575.
71. JN Mills, BA Ellis, KT McKee Jr, et al. (1991) Junin virus activity in rodents from endemic and nonendemic loci in central Argentina. Am J Trop Med Hyg 44(6), 589-597.
72. JN Mills, BA Ellis, KT McKee Jr, et al. (1992) A longitudinal study of Junin virus activity in the rodent reservoir of Argentine hemorrhagic fever. Am J Trop Med Hyg 47(6), 749-763.
73. Barren OHG, Eddy G. Characteristics of candidate live attenuated Junin virus vaccine. Program and Abstracts of the 4th International Conference on Comparative Virology, Banff, Canada 1982; abstract S4–S10.
74. KH Walen (1963) Demonstration of inapparent heterogeneity in a population of an animal virus by single-burst analyses. Virology 20 230-234.
75. KT McKee Jr, JG Oro, AI Kuehne, et al. (1992) Candid No. 1 Argentine hemorrhagic fever vaccine protects against lethal Junin virus challenge in rhesus macaques. Intervirology 34(3), 154-163.
76. KT McKee Jr, JG Oro, AI Kuehne, et al. (1993) Safety and immunogenicity of a live-attenuated Junin (Argentine hemorrhagic fever) vaccine in rhesus macaques. Am J Trop Med Hyg 48(3), 403-411.
77. MacDonald C, McKee K, Peters C, et al. Initial assessment of humans inoculated with a live-attenuated Junin virus vaccine. Program and abstracts of the 7th International Congress of Virology, Edmonton, Canada 1987.
78. Maiztegui JI, McKee KT, Jr. Inoculation of human volunteers with a vaccine against Argentine hemorrhagic fever. abstr. Program and Abstracts of the 6th International Conference on Comparative and Applied Virology, Banff, Canada 1989.
79. AM Ambrosio, LM Riera, MC Saavedra and MS Sabattini (2006) Immune response to vaccination against Argentine hemorrhagic fever in an area where different arenaviruses coexist. Viral Immunol 19(2), 196-201.
80. JI Maiztegui, KT McKee Jr, JG Barrera Oro, et al. (1998) Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever AHF Study Group. J Infect Dis 177(2), 277-283.
81. LH Harrison, NA Halsey, KT McKee Jr, et al. (1999) Clinical case definitions for Argentine hemorrhagic fever. Clin Infect Dis 28(5), 1091-1094.
82. DA Enria and JG Barrera Oro (2002) Junin virus vaccines. Curr Top Microbiol Immunol 263 239-261.
83. A Milazzo, R Hall, PA Storm, et al. (2001) Sexually transmitted Q fever. Clin Infect Dis 33(3), 399-402.
84. IA Penttila, RJ Harris, P Storm, et al. (1998) Cytokine dysregulation in the post-Q-fever fatigue syndrome. QJM 91(8), 549-560.
85. RA Ormsbee and BP Marmion (1990) Q Fever: Prevention of Coxiella burnetii infection: Vaccines and guidelines for those at risk. TJ Marne (Eds) The Disease 1 Boca Raton, FL: CRC Press 225-248.
86. JE Smadel and MJ Snyder (1948) Vaccination against Q fever. Am J Hyg 47 71-81.
87. DS Spicer and AN DeSanctis (1976) Preparation of phase 1Q fever antigen suitable for vaccine use. Appl Environ Microbiol 32(1), 85-88.
88. BP Marmion (1967) Develoopment of Q fever vaccines, 1937 to 1967. Med J Aust 2 1074-1078.
89. LBJF Luoto and MLDB Casey (1963) Q fever vaccination of human volunteers. I. Am J Hyg 78 1-15.
90. RA Shapiro, V Siskind, FD Schofield, et al. (1990) A randomized, controlled, double-blind, cross-over, clinical trial of Q fever vaccine in selected Queensland abattoirs. Epidemiol Infect 104(2), 267-273.
91. BP Marmion, RA Ormsbee, M Kyrkou, et al. (1984) Vaccine prophylaxis of abattoir-associated Q fever. Lancet 2(8417–18), 1411-1414.
92. JR Ackland, DA Worswick and BP Marmion (1994) Vaccine prophylaxis of Q fever. A follow-up study of the efficacy of Q-Vax (CSL) 1985–1990. Med J Aust 160(11), 704-708.
93. Beneson AS. Q fever vaccine: efficacy and present status. In: Smadel JE, (ed.). Symposium on Q Fever. Washington, DC: Walter Reed Army Institute of Medicine Science Publication No. 6; 47, 1959.
94. E Williams (1989) The Mediterranean Fever Commission: its origin and achievements. EJ Young, MJ Corbek (Eds) Brucellosis: Clinical Laboratory Aspects Boca Raton, FL: CRC Press 11-23.
95. LF Fries, DM Waag and JC Williams (1993) Safety and immunogenicity in human volunteers of a chloroform-methanol residue vaccine for Q fever. Infect Immun 61(4), 1251-1258.
96. J Kazar, R Brezina, A Palanova, et al. (1982) Immunogenicity and reactogenicity of a Q fever chemovaccine in persons professionally exposed to Q fever in Czechoslovakia. Bull World Health Organ 60(3), 389-394.
97. J Tyczka, S Eberling and G Baljer (2005) Immunization experiments with recombinant Coxiella burnetii proteins in a murine infection model. Ann N Y Acad Sci 1063 143-148.
98. G Zhang and JE Samuel (2004) Vaccines against Coxiella infection. Expert Rev Vaccines 3(5), 577-584.
99. E Francis (1919) Deer-fly or Pahvant Valley Plague: a disease of man of hitherto unknown etiology. Public Health Prev 34 2061-2062.
100. H Andersson, B Hartmanova, E Back, et al. (2006) Transcriptional profiling of the peripheral blood response during tularemia. Genes Immun 7(6), 503-513.
101. EL Overholt, WD Tigertt, PJ Kadull, et al. (1961) An analysis of forty-two cases of laboratory-acquired tularemia. Treatment with broad spectrum antibiotics. Am J Med 30 785-806.
102. MT Van Jr and PJ Kadull (1959) Laboratory-acquired tularemia in vaccinated individuals: a report of 62 cases. Ann Intern Med 50(3), 621-632.
103. L Foshay, WH Hesselbrock, HJ Wittenberg and AH Rodenberg (1942) Vaccine prophylaxis against tularemia in man. Am J Public Health 21 1131-1145.
104. PJ Kadull, HR Reames, LL Coriell and L Foshay (1950) Studies on tularemia. V. Immunization of man. J Immunol 65(4), 425-435.
105. S Saslaw, HT Eigelsbach, HE Wilson, et al. (1961) Tularemia vaccine study. I. Intracutaneous challenge. Arch Intern Med 107 689-701.
106. S Saslaw, HT Eigelsbach, JA Prior, et al. (1961) Tularemia vaccine study. II. Respiratory challenge. Arch Intern Med 107 702-714.
107. WD Tigertt (1962) Soviet viable Pasteurella tularensis vaccines. A review of selected articles. Bacteriol Rev 26 354-373.
108. Shope RE. An account of the observations made by the United States Medical Mission to the USSR. Mimeograph. Yale University; April, 1956.
109. HT Eigelsbach and CM Downs (1961) Prophylactic effectiveness of live and killed tularemia vaccines. I. Production of vaccine and evaluation in the white mouse and guinea pig. J Immunol 87 415-425.
110. HT Eigelsbach, DH Hunter, WA Janssen, et al. (1975) Murine model for study of cell-mediated immunity: protection against death from fully virulent Francisella tularensis infection. Infect Immun 12(5), 999-1005.
111. HT Eigelsbach, JJ Tulis, MH McGavran and JD White (1962) Live tularemia vaccine I. Host-parasite relationship in monkeys vaccinated intracutaneously or aerogenically. J Bacteriol 84(5), 1020-1027.
112. Hornick RB. Studies on Pasteurella tularensis: evaluation of a living vaccine for tularemia. Annual Report 1958; Ft. Detrick, MD: U.S. Army Medical Unit; Section II, 1–5.
113. S Saslaw and S Carhart (1961) Studies with tularemia vaccines in volunteers. III. Serologic aspects following intracutaneous or respiratory challenge in both vaccinated and nonvaccinated volunteers. Am J Med Sci 241 689-699.
114. McCrumb FRJ. Commission on epidemiological survey. Armed Forces Epidimiological Board, Office of the Surgeon General, United States Army, Washington, DC. Annual Report 81–86, 1962.
115. WD Sawyer, WD Tigertt and D Crozier (1962) Annual Progress Report Fort Detrick, MD: U.S. Army Medical Unit
116. CL Fuller, KC Brittingham, MJ Hepburn, et al. (2006) Dominance of human innate immune responses in primary Francisella tularensis live vaccine strain vaccination. J Allergy Clin Immunol 117(5), 1186-1188.
117. DS Burke (1977) Immunization against tularemia: analysis of the effectiveness of live Francisella tularensis vaccine in prevention of laboratory-acquired tularemia. J Infect Dis 135(1), 55-60.
118. KF Griffin, PC Oyston and RW Titball (2007) Francisella tularensis vaccines. FEMS Immunol Med Microbiol 49 315-323.
119. JA Marston (1861) Report on fever (Malta). Great Br Army Med Rep 3 486-521.
120. D Bruce (1887) Note on the recovery of a microorganism in Malta fever. Practitioner 39 161.
121. SJ Cutler, AM Whatmore and NJ Commander (2005) Brucellosis–new aspects of an old disease. J Appl Microbiol 98(6), 1270-1281.
122. D Luo, B Ni, P Li, et al. (2006) Protective immunity elicited by a divalent DNA vaccine encoding both the L7/L12 and Omp 16 genes of Brucella abortus in BALB/c mice. Infect Immun 74(5), 2734-2741.
123. AK Bhattacharjee, MJ Izadjoo, WD Zollinger, et al. (2006) Comparison of protective efficacy of subcutaneous versus intranasal immunization of mice with a Brucella melitensis lipopolysaccharide subunit vaccine. Infect Immun 74(10), 5820-5825.
124. J Cassataro, SM Estein, KA Pasquevich, et al. (2005) Vaccination with the recombinant Brucella outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4 + T helper 1 response that protects against Brucella melitensis infection. Infect Immun 73(12), 8079-8088.
125. J Cassataro, CA Velikovsky, S de la Barrero, et al. (2005) A DNA vaccine coding for the Brucella outer membrane protein 31 confers protection against B. melitensis and B. ovis infection by eliciting a specific cytotoxic response. Infect Immun 73(10), 6537-6546.
126. X Yang, M Hudson, N Walters, et al. (2005) Selection of protective epitopes for Brucella melitensis by DNA vaccination. Infect Immun 73(11), 7297-7303.
127. AK Bhattacharjee, d Van, L Verg, MJ Izadjoo, et al. (2002) Protection of mice against brucellosis by intranasal immunization with Brucella melitensis lipopolysaccharide as a noncovalent complex with Neisseria meningitidis group B outer membrane protein. Infect Immun 70(7), 3324-3329.
128. UB Schaad, AB Lang, J Wedgwood, et al. (1991) Safety and immunogenicity of Pseudomonas aeruginosa conjugate A vaccine in cystic fibrosis. Lancet 338(8777), 1236-1237.
129. AW Zuercher, MP Horn, JU Que, et al. (2006) Antibody responses induced by long-term vaccination with an octovalent conjugate Pseudomonas aeruginosa vaccine in children with cystic fibrosis. FEMS Immunol Med Microbiol 47(2), 302-308.
130. AW Zuercher, MA Imboden, S Jampen, et al. (2006) Cellular immunity in healthy volunteers treated with an octavalent conjugate Pseudomonas aeruginosa vaccine. Clin Exp Immunol 143(1), 132-138.
131. AB Lang, UB Schaad, A Rudeberg, et al. (1995) Effect of high-affinity anti- Pseudomonas aeruginosa lipopolysaccharide antibodies induced by immunization on the rate of Pseudomonas aeruginosa infection in patients with cystic fibrosis. J Pediatr 127(5), 711-717.
132. Herzog C, Personal communication to S. Plotkin, November 26, 2002 2002.
133. AB Lang, A Rudeberg, MH Schoni, et al. (2004) Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection. Pediatr Infect Dis J 23(6), 504-510.
134. AB Lang and IC Metcalfe (2002) Vaccination against Pseudomonas aeruginosa: clincal trial results Genova: S;A: Monduzzi Editore
135. AB Lang, MP Horn, MA Imboden and AW Zuercher (2004) Prophylaxis and therapy of Pseudomonas aeruginosa infection in cystic fibrosis and immunocompromised patients. Vaccine 22(Suppl 1), S44-S48.
136. AW Cripps, K Peek, M Dunkley, et al. (2006) Safety and immunogenicity of an oral inactivated whole-cell pseudomonas aeruginosa vaccine administered to healthy human subjects. Infect Immun 74(2), 968-974.
137. C Theilacker, FT Coleman, S Mueschenborn, et al. (2003) Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine. Infect Immun 71(7), 3875-3884.
138. A Digiandomenico, J Rag, K Harcher, et al. (2007) Intranasal immunization with heterologously expressed polysaccharide protects against multiple Pseudomonas aeruginosa infections. Proc Natl Acad Sci USA 104(11), 4624-4629.
139. TS Zaid, GP Priebe and GB Pier (2006) A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection. Infect Immun 74(2), 975-983.
140. SS Arnon (1995) Botulism as an intestinal toxemia. MJ Blaser, PD Smith, JI Ravdin, et al., (Eds) Infections of the Intestinal Tract 1995 New York: Raven Press 257-271.
141. AB Scott (1980) Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. J Pediatr Ophthalmol Strabismus 17(1), 21-25.
142. EJ Schantz and EA Johnson (1992) Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev 56(1), 80-99.
143. J Jakovic and M Hallet (Eds) (1994) Therapy with Botulinum Toxin New York: Marcel Dekker
144. MA Fiock, MA Cardella and NF Gearinger (1963) Studies on immunity to toxins of Clostridium botulinum. IX. Immunologic response of man to purified pentavalent ABCDE botulinum toxoid. J Immunol 90 697-702.
145. PR Pittman, D Hack, J Mangiafico, et al. (2002) Antibody response to a delayed booster dose of anthrax vaccine and botulinum toxoid. Vaccine 20(16), 2107-2115.
146. DR Franz, PB Jahrling, AM Friedlander, et al. (1997) Clinical recognition and management of patients exposed to biological warfare agents. JAMA 278(5), 399-411.
147. JT Weber, RG Hibbs Jr, A Darwish, et al. (1993) A massive outbreak of type E botulism associated with traditional salted fish in Cairo. J Infect Dis 167(2), 451-454.
148. RG Hibbs, JT Weber, A Corwin, et al. (1996) Experience with the use of an investigational F(ab′)2 heptavalent botulism immune globulin of equine origin during an outbreak of type E botulism in Egypt. Clin Infect Dis 23(2), 337-340.